Eli Lilly News | finanzen.ch

Eli Lilly Aktie VALOR 947556 / ISIN US5324571083

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

10.10.22	Innovent Biologics : China Approves SNDA For CYRAMZA For Hepatocellular Carcinoma Treatment (RTTNews)
10.10.22	Innovent Biologics: China Oks Selpercatinib NDA For Treatment Of RET-driven Lung And Thyroid Cancers (RTTNews)
06.10.22	Eli Lilly Gets Fast Track Status For Its Tirzepatide To Treat Obesity (RTTNews)
06.10.22	Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities (PR Newswire)
28.09.22	Pre-market Movers: SILO, PRTA, BIIB, NXPL, ABOS… (RTTNews)
22.09.22	Lilly : FDA Approves Retevmo For Adult Patients With Locally Advanced Or Metastatic Solid Tumors (RTTNews)
22.09.22	FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type (PR Newswire)
08.09.22	Eli Lilly: Late-breaking Lebrikizumab Data Shows Long-lasting Results In Atopic Dermatitis (RTTNews)
08.09.22	Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials (PR Newswire)
08.09.22	Lilly Announces Details of Presentations at ESMO Congress 2022 (PR Newswire)
31.08.22	Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference (PR Newswire)
25.08.22	Lilly to Participate in Citi's 17th Annual BioPharma Conference (PR Newswire)
11.08.22	Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly (PR Newswire)
08.08.22	Eli Lilly Says New Formulation Of Taltz Injection Available Across US (RTTNews)
08.08.22	Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience (PR Newswire)
08.08.22	HUTCHMED Stock Up As Fruquintinib Global Phase III FRESCO-2 Study In CRC Meets Primary Goal (RTTNews)
04.08.22	Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results (PR Newswire)
04.08.22	Eli Lilly Reduces FY22 Earnings Guidance; Revenue Outlook Remains Unchanged (RTTNews)
04.08.22	Eli Lilly And Co. Profit Declines In Q2 (RTTNews)
04.08.22	Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements (PR Newswire)
21.07.22	Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement (PR Newswire)
29.06.22	Lilly To Supply Addl. 150K Doses Of Bebtelovimab To U.S. Government For About $275 Mln (RTTNews)
29.06.22	Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options (PR Newswire)
27.06.22	Lilly Declares Third-Quarter 2022 Dividend (PR Newswire)
27.06.22	Statement of changes in beneficial ownership of securities (RSS)
27.06.22	Lilly : China Approves TYVYT Combination For Treatment Of Gastric Cancer (RTTNews)
24.06.22	Statement of changes in beneficial ownership of securities (RSS)
23.06.22	Statement of changes in beneficial ownership of securities (RSS)
21.06.22	Innovent : China Approves TYVYT Combination As Treatment For Esophageal Squamous Cell Carcinoma (RTTNews)
14.06.22	FDA Approves First Medicine Ever For Alopecia Areata (RTTNews)
14.06.22	FDA Approves Lilly's Olumiant As First Systemic Treatment For Alopecia (RTTNews)
14.06.22	FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata (PR Newswire)
07.06.22	Lilly Reports Positive Data From Lebrikizumab Atopic Dermatitis Monotherapy Trials (RTTNews)
07.06.22	Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials (PR Newswire)
07.06.22	New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions® (PR Newswire)
06.06.22	Lilly : Jardiance Decreases Risk Of Hospitalization For Heart Failure By 50% In Type 2 Diabetes (RTTNews)
05.06.22	Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world eviden... (PR Newswire)
04.06.22	Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo (PR Newswire)
04.06.22	Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight (PR Newswire)
03.06.22	Lilly to Participate in Goldman Sachs Global Healthcare Conference (PR Newswire)
31.05.22	Statement of changes in beneficial ownership of securities (RSS)
26.05.22	Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
26.05.22	Lilly To Invest $2.1 Bln In New Manufacturing Sites In Indiana (RTTNews)
25.05.22	Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana (PR Newswire)
25.05.22	Statement of changes in beneficial ownership of securities (RSS)
24.05.22	Lilly: One-half Of Mirikizumab Patients Achieves Clinical Remission At One Year In Phase 3 Study (RTTNews)
24.05.22	Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study (PR Newswire)
23.05.22	Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA (PR Newswire)
20.05.22	Lilly : CHMP Issues Positive Opinion For Olumiant For Severe Alopecia Areata Treatment (RTTNews)
20.05.22	CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA) (PR Newswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Holcim	89.10	3.05 %	K V
Part Grp Hldg	1’084.50	2.75 %	K V
Zurich Insur Gr	553.60	2.52 %	K V
Swiss Life Hldg	775.80	2.43 %	K V
Geberit	559.60	2.15 %	K V
Sonova Hldg	234.00	-0.68 %	K V
CieFinRichemont	135.80	-0.88 %	K V
UBS Group	23.20	-1.11 %	K V
Swiss Re	139.80	-1.48 %	K V
Logitech Intl	59.66	-1.71 %	K V

mehr

16:02		Dow Jones 30 Industrial-Wert Merck-Aktie: So viel Verlust hätte ein Investment in Merck von vor einem Jahr bedeutet
16:02		S&P 500-Papier Pfizer-Aktie: So viel Verlust hätte ein Investment in Pfizer von vor einem Jahr bedeutet
16:02		S&P 500-Wert Eli Lilly-Aktie: So viel hätte eine Investition in Eli Lilly von vor 5 Jahren abgeworfen
14.04.25		Pfizer-Aktie dennoch fester: Entwicklung von Abnehmpille gestoppt
14.04.25		DAX 40-Wert Merck-Aktie: So viel Verlust hätte eine Merck-Investition von vor 3 Jahren eingebracht
14.04.25		SMI-Papier Novartis-Aktie: Wäre eine Novartis-Investition von vor einem Jahr rentabel gewesen?
14.04.25		Neue Analyse: Jefferies & Company Inc. bewertet Bayer-Aktie mit Hold
14.04.25		Erste Schätzungen: Pfizer stellt Ergebnisse des abgelaufenen Quartals vor